Cargando…

Variability in functional p53 reactivation by PRIMA-1(Met)/APR-246 in Ewing sarcoma

BACKGROUND: Though p53 mutations are rare in ES, there is a strong indication that p53 mutant tumours form a particularly bad prognostic group. As such, novel treatment strategies are warranted that would specifically target and eradicate tumour cells containing mutant p53 in this subset of ES patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aryee, D N T, Niedan, S, Ban, J, Schwentner, R, Muehlbacher, K, Kauer, M, Kofler, R, Kovar, H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3833220/ https://www.ncbi.nlm.nih.gov/pubmed/24129240 http://dx.doi.org/10.1038/bjc.2013.635

Ejemplares similares

Suppression of FOXO1 is responsible for a growth regulatory repressive transcriptional sub-signature of EWS-FLI1 in Ewing sarcoma
por: Niedan, S, et al.
Publicado: (2014)

Antitumor Effects of PRIMA-1 and PRIMA-1(Met) (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?
por: Menichini, Paola, et al.
Publicado: (2021)

Factors Affecting EWS-FLI1 Activity in Ewing's Sarcoma
por: Herrero-Martin, David, et al.
Publicado: (2011)

Improvement of epidermal covering on AEC patients with severe skin erosions by PRIMA-1(MET)/APR-246
por: Aberdam, Edith, et al.
Publicado: (2020)

PRIMA-1(met) (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanisms
por: Li, Xiao-Lan, et al.
Publicado: (2015)

Synergistic effects of PRIMA-1(Met) (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia
por: Maslah, Nabih, et al.
Publicado: (2020)

A Molecular Function Map of Ewing's Sarcoma
por: Kauer, Maximilian, et al.
Publicado: (2009)

PRIMA-1 and PRIMA-1(Met) (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies
por: Perdrix, Anne, et al.
Publicado: (2017)

Cellular and humoral mechanisms of osteoclast formation in Ewing's sarcoma
por: Lau, Y S, et al.
Publicado: (2007)

APR-246/PRIMA-1(MET) inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase
por: Peng, X, et al.
Publicado: (2013)

APR-246/PRIMA-1(MET) inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase
por: Peng, Xiaoxiao, et al.
Publicado: (2017)

The role of miR-17-92 in the miRegulatory landscape of Ewing sarcoma
por: Schwentner, Raphaela, et al.
Publicado: (2016)

EWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cells
por: Mutz, Cornelia N., et al.
Publicado: (2017)

EWS-FLI1 perturbs MRTFB/YAP-1/TEAD target gene regulation inhibiting cytoskeletal autoregulatory feedback in Ewing sarcoma
por: Katschnig, A M, et al.
Publicado: (2017)

YAP/TAZ inhibition reduces metastatic potential of Ewing sarcoma cells
por: Bierbaumer, Lisa, et al.
Publicado: (2021)

PRIMA-1(MET) induces death in soft-tissue sarcomas cell independent of p53
por: Grellety, Thomas, et al.
Publicado: (2015)

Stable interference of EWS–FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target
por: Herrero-Martín, D, et al.
Publicado: (2009)

APR-246 increases tumor antigenicity independent of p53
por: Michels, Judith, et al.
Publicado: (2023)

Basic fibroblast growth factor in the bone microenvironment enhances cell motility and invasion of Ewing's sarcoma family of tumours by activating the FGFR1–PI3K–Rac1 pathway
por: Kamura, S, et al.
Publicado: (2010)

MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines
por: Arriola, E, et al.
Publicado: (2011)

The First European Interdisciplinary Ewing Sarcoma Research Summit
por: Kovar, Heinrich, et al.
Publicado: (2012)

Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification
por: Tanizaki, J, et al.
Publicado: (2011)

Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma
por: Miyamoto, M, et al.
Publicado: (2011)

Zooming in on Long Non-Coding RNAs in Ewing Sarcoma Pathogenesis
por: Aryee, Dave N. T., et al.
Publicado: (2022)

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
por: Sallman, David A., et al.
Publicado: (2021)

High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer
por: Zagouri, F, et al.
Publicado: (2013)

Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer
por: Bilke, Sven, et al.
Publicado: (2013)

Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma
por: Tuynman, J B, et al.
Publicado: (2008)

Associations between hepatocyte growth factor, c-Met, and basic fibroblast growth factor and survival in endometrial cancer patients
por: Felix, A S, et al.
Publicado: (2012)

c-Met overexpression in inflammatory breast carcinomas: automated quantification on tissue microarrays
por: Garcia, S, et al.
Publicado: (2007)

Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer
por: Hofstetter, G, et al.
Publicado: (2011)

The tumour suppressor miR-34c targets MET in prostate cancer cells
por: Hagman, Z, et al.
Publicado: (2013)

APR-246 reactivates mutant p53 by targeting cysteines 124 and 277
por: Zhang, Qiang, et al.
Publicado: (2018)

Stabilisation of p53 enhances reovirus-induced apoptosis and virus spread through p53-dependent NF-κB activation
por: Pan, D, et al.
Publicado: (2011)

PRIMA-1(MET) Inhibits Growth of Mouse Tumors Carrying Mutant p53
por: Zache, Nicole, et al.
Publicado: (2008)

Unique volatolomic signatures of TP53 and KRAS in lung cells
por: Davies, M P A, et al.
Publicado: (2014)

Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder
por: Cheng, H-L, et al.
Publicado: (2005)

Identifying the druggable interactome of EWS-FLI1 reveals MCL-1 dependent differential sensitivities of Ewing sarcoma cells to apoptosis inducers
por: Tsafou, Kalliopi, et al.
Publicado: (2018)

MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome
por: Lee, H E, et al.
Publicado: (2012)

p63 is required beside p53 for PERP-mediated apoptosis in uveal melanoma
por: Awais, Raheela, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ohs19sit29fk67kckhbvoc6tpq